After setbacks, cema-cel might have a path to approval in lymphoma.
ApexOnco Front Page
Recent articles
Optimum-02 virtually replicates phase 1, and a filing will follow.
The oncolytic virus vuso-vec is slapped with its second CRL.
The group impresses in ovarian and endometrial cancers.
After opting in last year, Gilead picks up Kymera's KT-200.
The industry’s first ALK degrader starts its first human study.
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
